PT Pyridam Farma Tbk (ISX:PYFA) EBIT: Rp-200,691 Mil (TTM As of Mar. 2026)


ISX:PYFA PT Pyridam Farma Tbk ISX:PYFA
68 GF Score
Price Rp182.00
GF Value Rp212.90
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is PT Pyridam Farma Tbk EBIT?

PT Pyridam Farma Tbk ISX:PYFA -1.09% 68 EBIT is Rp-200,691 Mil as of Mar. 2026. GuruFocus rates ISX:PYFA with a GF Score™ of 68/100 and a GF Value™ of Rp212.90 (Modestly Undervalued). The stock has 8 warning signs investors should review.

PT Pyridam Farma Tbk's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was Rp-6,995 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was Rp-200,691 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Pyridam Farma Tbk's annualized ROC % for the quarter that ended in Mar. 2026 was -0.57%. PT Pyridam Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -0.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Pyridam Farma Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.76%.


PT Pyridam Farma Tbk  (ISX:PYFA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Pyridam Farma Tbk's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-37868.592 * ( 1 - 2.93% )/( (6226595.411 + 6744665.112)/ 2 )
=-36759.0422544/6485630.2615
=-0.57 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6771130.415 - 441647.225 - ( 102887.779 - max(0, 1145961.299 - 1421703.96+102887.779))
=6226595.411

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7066339.232 - 575864.802 - ( 51070.682 - max(0, 1765947.864 - 1511757.182+51070.682))
=6744665.112

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Pyridam Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-27979.396/( ( (2375522.017 + max(616307.142, 0)) + (2399586.962 + max(631350.852, 0)) )/ 2 )
=-27979.396/( ( 2991829.159 + 3030937.814 )/ 2 )
=-27979.396/3011383.4865
=-0.93 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(755688.722 + 483970.543 + 73929.147) - (441647.225 + 0 + 255634.045)
=616307.142

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(828625.767 + 540997.574 + 79505.193) - (575864.802 + 0 + 241912.88)
=631350.852

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Pyridam Farma Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-200691.203/7272804.377
=-2.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Pyridam Farma Tbk EBIT Related Terms


PT Pyridam Farma Tbk EBIT Historical Data

* Premium members only.

The historical data trend for PT Pyridam Farma Tbk's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Pyridam Farma Tbk EBIT Chart

PT Pyridam Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50,738.12 342,538.68 2,546.61 -100,946.42 -212,734.52

PT Pyridam Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19,038.16 -46,090.21 -65,792.76 -81,813.39 -6,994.85

ISX:PYFA vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Pyridam Farma Tbk EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Pyridam Farma Tbk's EV-to-EBIT falls into.


ISX:PYFA
68GF Score
PT Pyridam Farma Tbk ISX:PYFA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Pyridam Farma Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-200,691 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of Rp-200,691 Mil mean?
PT Pyridam Farma Tbk (ISX:PYFA) has a EBIT of Rp-200,691 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Pyridam Farma Tbk.
Is PT Pyridam Farma Tbk's EBIT too high?
PT Pyridam Farma Tbk's current EBIT is Rp-200,691 Mil. Overall, PT Pyridam Farma Tbk has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's EBIT compare to ZTS and UTHR?
PT Pyridam Farma Tbk's EBIT of Rp-200,691 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Pyridam Farma Tbk. PT Pyridam Farma Tbk's current EBIT is Rp-200,691 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp212.90, compared to a current price of Rp182.00 — trading 14.5% below its estimated fair value. The current EBIT is Rp-200,691 Mil. PT Pyridam Farma Tbk's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current EBIT is Rp-200,691 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued. The current stock price of Rp182.00 is trading 14.5% below its estimated GF Value™ of Rp212.90. GuruFocus considers PT Pyridam Farma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:PYFA:

  • EBIT: Rp-200,691 Mil
  • GF Value™: Rp212.90 vs. price of Rp182.00 (14.5% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Pyridam Farma Tbk Business Description

Address Jl. Jenderal Sudirman Kav. 21, Sinar Mas Land Plaza Sudirman 12th Floor, RT 10/RW 01 Kuningan, Karet, Jakarta Selatan, Jakarta, IDN, 12920
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
68GF Score

Get the complete analysis for ISX:PYFA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp182.00
Price
Rp212.90
GF Value